Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

BACKGROUND: Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB–IVM1c melanoma. METHODS: Patients were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Andtbacka, Robert H. I., Collichio, Frances, Harrington, Kevin J., Middleton, Mark R., Downey, Gerald, Ӧhrling, Katarina, Kaufman, Howard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554874/
https://www.ncbi.nlm.nih.gov/pubmed/31171039
http://dx.doi.org/10.1186/s40425-019-0623-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554874/
https://www.ncbi.nlm.nih.gov/pubmed/31171039
http://dx.doi.org/10.1186/s40425-019-0623-z

Ejemplares similares